British Guideline on the management of asthma
306. Table 16: nedocromil and sodium cromoglycate studies not included in the nedocromil meta-analysis. In: North of England Evidence Based Guideline Development Project, editor. The primary care management of asthma in adults. Newcastle upon Tyne: University of Newcastle upon Tyne, Centre for Health Services Research; 1999. p.46-7. 307. Pharmacological management of asthma. Evidence table 4.4j: Do cromones works as first line preventor in children >5 years? Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/ published/support/guideline63/index.html 308. Pharmacological management of asthma. Evidence table 4.24b: Other preventor therapies - Chromones in children aged <5. Edinburgh: SIGN; 2005. Available from url: Available from url: http://www.sign. ac.uk/guidelines/published/support/guideline63/index.html 309. Pharmacological management of asthma. Evidence table 4.4d: leukotriene receptor antagonists with short-acting beta-agonists. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/ guidelines/published/support/guideline63/index.html 310. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003;362(7390):621. 311. Van Ganse E, Kaufman L, Derde MP, Yernault JC, Delaunois L, Vincken W. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J 1997;10(10):2216-24. 312. Pharmacological management of asthma. Evidence table 4.11b: Add-on drugs for inhaled steroids: long acting or oral B2 agonists. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/ published/support/guideline63/index.html 313. Pharmacological management of asthma. Evidence table 4.11d: Add-on drugs for inhaled steroids: theophylline, beclometasone diproponate, budesonide. Edinburgh: SIGN; 2002. Available from url: http://www. sign.ac.uk/guidelines/published/support/guideline63/index.html 314. Pharmacological management of asthma. Evidence table 4.11c: Add-on drugs for inhaled steroids: anticholinergics. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/ guideline63/index.html 315. Pharmacological management of asthma. Evidence table 4.11a: Addon drugs for inhaled steroids: cromones. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/ guideline63/index.html 316. Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol 1989;84(6 Pt 1):891-5. 317. Kips JC, Pauwels RA. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit Care Med 2001;164(6):923-32. 318. Pharmacological management of asthma. Evidence table 4.22: Combined therapy of inhaled steroids and long acting B2 agonists. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/ guidelines/published/support/guideline63/index.html 319. Pharmacological management of asthma. Evidence table 4.8c: Children with poor asthma control on ICS - is addition of leukotriene receptor antagonists helpful? Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/guideline63/index. html 320. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108(3):E48. 321. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. London: John Wiley & Sons Ltd. 322. British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London in association with the General Practitioner in Asthma Group, The British Association of Accident and Emergency Medicine, The British Paediatric Respiratory Society, Royal College of Paediatrics and Child Health. The British guidelines on asthma management 1995 review and position statement. Thorax 1997;52(Suppl 1):S1-S21. 323. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61(5):725-36. 324. O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171(2):129-36. 325. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;368(9537):744-53. 326. Scicchitano. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and opinions 2004;20(9):1403-18. 327. Vogelmeier C, D’Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26(5):819-28.
128
328. National Osteoporosis Society. Guidance on the prevention and management of corticosteroid induced osteoporosis. Bath: National Osteoporosis Society; 1998. 329. Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med 1981;304(2):71-5. 330. Pharmacological management of asthma. Evidence table 4.13a: Immunosuppresive agents. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/guideline63/index. html 331. O’Driscoll BR, Ruffles SP, Ayres JG, Cochrane GM. Long term treatment of severe asthma with subcutaneous terbutaline. Br J Dis Chest 1988;82(4):360-7. 332. Payne D, Balfour-Lynn I, Biggart E, Bush A, Rosenthal M. Subcutaneous terbutaline in children with chronic severe asthma. Pediatr Pulmonol. 2002;33(5):356-61. 333. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma N Engl J Med. 2006;354(7):697-708. 334. Hawkins G, McMahon AD, Twaddle S, Wood S, Ford I, NC. T. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003;326(7399):1115. 335. Pharmacological management of asthma. Evidence table 4.9: Exacerbation. Edinburgh: SIGN; 2002. Available from url: http://www. sign.ac.uk/guidelines/published/support/guideline63/index.html 336. Reference deleted 337. Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol 1992;89(6):1176-82. 338. Pharmacological management of asthma. Evidence table 4.3a: Long acting B2 agonists in exercise induced asthma. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/ guideline63/index.html 339. Pharmacological management of asthma. Evidence table 4.3c: Theophyllines in exercise-induced asthma. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/ guideline63/index.html 340. Pharmacological management of asthma. Evidence table 4.3d: Leukotriene receptor antagonists in exercise induced asthma. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/ published/support/guideline63/index.html 341. Kelly K, Spooner CH, Rowe BH. Nedocromil sodium versus sodium cromoglycate for preventing exercise-induced bronchoconstriction in asthmatics (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. London: John Wiley & Sons Ltd. 342. Pharmacological management of asthma. Evidence table 4.3g: Oral B2 agonists for exercise induced asthma. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/ guideline63/index.html 343. Pharmacological management of asthma. Evidence table 4.3f: Anticholinergic therapy for exercise-induced asthma. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/ support/guideline63/index.html 344. Pharmacological management of asthma. Evidence table 4.3b: Ketotifen for exercise-induced asthma. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/guideline63/ index.html 345. Pharmacological management of asthma. Evidence table 4.3e: Antihistamines for exercise-induced asthma. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/ guideline63/index.html 346. Pharmacological management of asthma. Evidence table 4.10: Rhinitis. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/ guidelines/published/support/guideline63/index.html 347. Pharmacological management of asthma. Evidence table 4.19: Allergic bronchopulmonary aspergillosis. Edinburgh: SIGN; 2002. Available from url: http://www.sign.ac.uk/guidelines/published/support/ guideline63/index.html 348. Wark PAB, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. London: John Wiley & Sons Ltd. 349. Pharmacological management of asthma. Evidence table 4.21: Aspirin intolerant asthma. Edinburgh: SIGN; 2002. Available from url: http:// www.sign.ac.uk/guidelines/published/support/guideline63/index. html 350. Coughlan J. Oesophagitis does not consistently improve asthma control: A systematic review. . Thorax 2001;56(3):198-204. 351. Gibson PG, Henry RL, Coughlan JL. Gastro oesophogeal reflux treatment for asthma in adults and children (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. London: John Wiley & Sons Ltd.